Hsbc Holdings PLC Cuts Stake in Sanofi $SNY

Key Points

• Hsbc Holdings PLC has significantly reduced its stake in Sanofi by 76.8%, now holding only 8,130 shares after selling 26,903 shares in the first quarter.
• Sanofi's recent earnings report showed an EPS of $0.90, missing estimates of $0.96 despite a revenue of $11.34 billion.
• Analysts are generally optimistic on Sanofi, with a consensus rating of "Buy" and an average price target of $62.00, indicating potential upside for investors.

Hsbc Holdings PLC lessened its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 76.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,130 shares of the company's stock after selling 26,903 shares during the quarter. Hsbc Holdings PLC's holdings in Sanofi were worth $453,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of Sanofi in the first quarter valued at about $177,831,000. Federated Hermes Inc. raised its stake in Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock worth $218,933,000 after purchasing an additional 1,456,269 shares during the period. Point72 Asset Management L.P. raised its stake in Sanofi by 969.6% during the fourth quarter. Point72 Asset Management L.P. now owns 950,649 shares of the company's stock worth $45,850,000 after purchasing an additional 861,770 shares during the period. Vestal Point Capital LP raised its stake in Sanofi by 400.0% during the fourth quarter. Vestal Point Capital LP now owns 750,000 shares of the company's stock worth $36,172,000 after purchasing an additional 600,000 shares during the period. Finally, Northern Trust Corp raised its stake in Sanofi by 44.9% during the fourth quarter. Northern Trust Corp now owns 1,930,560 shares of the company's stock worth $93,111,000 after purchasing an additional 597,959 shares during the period. Institutional investors and hedge funds own 14.04% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on SNY shares. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Guggenheim reissued a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Stock Down 9.1%

SNY traded down $4.56 during trading hours on Thursday, hitting $45.33. 8,957,428 shares of the company's stock were exchanged, compared to its average volume of 2,575,101. Sanofi has a 12-month low of $44.73 and a 12-month high of $60.12. The firm has a 50 day moving average of $48.90 and a 200 day moving average of $51.51. The firm has a market cap of $111.31 billion, a P/E ratio of 10.90, a price-to-earnings-growth ratio of 1.18 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The business had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. During the same period in the previous year, the company earned $1.73 earnings per share. Sanofi's quarterly revenue was down 7.0% on a year-over-year basis. Analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.